Abstract: Novel ligands for use in MRI contrast agents and which have the formula ##STR1## wherein R.sub.1 -R.sub.14, M", l, m, and n are defined herein.

Abstract: Proteins containing one or more disulfide bonds or monosulfides are labeled with medically useful metal ions for use in diagnosis and treatment of a variety of pathologic conditions. Labeling is accomplished with a variety of metals, including radiometals, by using a reducing agent to reduce the disulfide bonds to thiolate groups; excess reducing agent, reaction by-products and any impurities are removed; and, a source of Sn (II) agent is added to the thiolate-containing protein. The resulting product may be stored frozen or lyophilized, with labeling accomplished by the addition of the medically useful metal ions.

Abstract: A method and test kit for determining tumor cell apoptosis by inhibition of 12-lipoxygenase is described. A method for selectively inducing tumor cell apoptosis by inhibiting 12-lipoxygenase is also described. The preferred compounds are selected from the group consisting of a cyclic hydroxamic acid; and an aryl aliphatic acid; nordihydro guaiaretic acid (NDGA) and N-benzyl-N-hydroxy-5-phenylpentanamide (BHPP).

Abstract: Disclosed are a method for quantitative determination of bilirubin and a reagent for the method, which are useful in clinical examinations. The method comprises subjecting the bilirubin in a sample to coexist with ascorbate oxidase and a reaction promoter in aqueous medium to thereby oxidize the bilirubin, measuring the change in absorbance of the aqueous medium and comparing the change in absorbance with a calibration curve. The reagent comprises ascorbate oxidase and a reaction promoter.

Abstract: The invention concerns a method for the simultaneous colorimetric and electrochemical measurement of an analyte using an oxidizing enzyme and a chromogen A that accepts electrons from the enzyme which is characterized in that the chromogen A after reduction to A' reacts by coupling to a substance BX to form a colored substance A'B the concentratin of which is measured colorimetrically as a measure for the presence or amount of the analyte and in that an electrochemically measurable group X.sup.- is cleaved off during the coupling reaction the concentration of which is measured electrochemically as a measure for the amount of the analyte.

Abstract: This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents, methods and kits for making the agents, and methods for using the agents to image pathological sites, including sites of infection, inflammation, cancer and atherosclerosis in a mammalian body. Specifically the agents and reagents are derivatives of oligosaccharides, more specifically .beta.-glucans.

Abstract: The invention relates to new 3,8-substituted deuteroporphyrin derivatives with various substituents in positions 13 and 17 of the porphyrin skeleton, pharmaceutical agents containing these compounds, their use in diagnosis and therapy as well as process for the production of these agents.

Abstract: This invention relates to radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic and radiotherapeutic agents. Specifically, the invention relates to VIP receptor binding peptides, derivatives and analogues of VIP, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to VIP receptor binding peptide derivatives and analogues of VIP radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to VIP receptor binding peptide derivatives and analogues of VIP radiolabeled with cytotoxic radioisotopes such as rhenium-186 (.sup.186 Re) and rhenium-188 (.sup.188 Re) for use as radiotherapeutic agents.

Abstract: This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to specific binding peptides, methods and kits for making such peptides, and methods for using such peptides labeled with technetium-99m via a radiolabel-binding moiety covalently linked to the peptide to image thrombus sites in a mammalian body.

Abstract: Radioactively labelled peptides comprising oligopeptides of from 3 to 10 peptide units and containing the sequence RGD and particularly the oligopeptides RGDSY and RGDFY, are disclosed as in vivo thrombus, tumour or CAM markers for the in vivo diagnosis and detection or thrombi, tumours or CAM in mammals.

Abstract: A method for bioassaying for metabolic activation of toxicants from a xenobiotic compound by a metabolic enzyme system includes incubating the xenobiotic compound with a metabolic enzyme system known to produce toxicants during normal metabolic degradation processes and with a mitochondrial membrane preparation competent for enzymatic electron transfer. The production of a toxicant has a detrimental effect upon the electron transfer activity of the mitochondrial membrane preparation which can readily be assayed by observing changes in concentration of a selected redox indicator.

Abstract: A diagnostic agent for hypoxia or mitochondrial dysfunction is disclosed, comprising a radioactive copper complex of a dithiosemicarbazone derivative or a radioactive copper complex of a diamine diol schiff base derivative. This agent has good transferability to the target tissue, reduction reaction affinity at a hypoxic site, high stability in a non-target site and rapidly disappears.

Abstract: Anticancer, antimicrobial and autoimmune disease, and anti-organ rejection therapy using cytotoxic agents is improved using cytokines to prevent, mitigate or reverse adverse radiation-induced or drug-induced toxicity, especially to hematopoietic cells. Cytotoxic agents can include radioisotopes, drugs, toxins and even unconjugated cytotoxic antibodies. A preferred cytokine is IL-1. Higher doses of cytotoxic agents can be administered and tolerated by the patient and dose-limiting marrow toxicity can be prevented, palliated or reversed using adjunct cytokine therapy.

Abstract: This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents, methods and kits for making the agents, and methods for using the agents to image pathological sites, including sites of infection, inflammation, cancer and atherosclerosis in a mammalian body. Specifically the agents and reagents are derivatives of oligosaccharides, more specifically .beta.-glucans.

Abstract: Delivery to the colon of fatty acids especially Short Chain Fatty Acids (SCFA) can be effected by covalently linking SCFA to a carrier that is preferably a form of carbohydrate, by an ester link. The SCFA is protected by its link with the carbohydrate through the small intestine, and where the carbohydrate is digestible in the small intestine such as a digestible starch, the starch can also be protected from digestion in the small intestine by the substitution. Levels of SCFA such as acetate, propionate and butyrate may be elevated to have beneficial effects in the prevention of colonic disorders such as rectal cancer, diverticulities, colitis, diarrhea and constipation.

Abstract: This invention relates an .alpha.-glucosidase inhibitor mildly inhibiting .alpha.-glucosidase locally present in the micro-villus of small intestine, a composition principally comprising sugar and containing the inhibitor, a food, a sweetener and a feed. The inhibitor delays the digestion of starch, starch-derived oligosaccharides and sucrose, so that the inhibitor has an action of suppressing rapid increase in blood glucose level and an action of suppressing insulin secretion at a lower level. Thus, the inhibitor is useful for the prophylaxis of obesity and diabetes mellitus. The .alpha.-glucosidase inhibitor of the present invention is composed of nucleotide, nucleoside, or base as the structural component of nucleic acid and one or two or more digestible sugars selected from sucrose, starch and starch-derived oligosaccharide. The .alpha.-glucosidase inhibitor mildly inhibits the action of .alpha.

Abstract: A method for imaging foci of infection by administering radiolabeled human IgM 16.88 and detecting sites of localization.

Abstract: The present invention provides a labelled acyl-L-carnitine, which is an acyl-L-carnitine, a salt thereof or a derivative thereof, of which carbon group is labelled with a radionuclide or a stable isotope. It is possible to diagnose human diseases falling under acyl-carnitine metabolic syndrome, or human diseases due to structural/functional disorder of the brain by measuring the behavior of the labelled acyl-L-carnitine in various tissues or a biological sample from a subject administered with one or more kinds of the labelled acyl-L-carnitines.

Abstract: Detectably labelled non-receptor mediated cell-associating compounds are provided for use in the diagnostic imaging of target sites in a mammal. Cell-associating compounds may be directly labelled, or labelled via a chelating compound to form a conjugate. Such cell-associating compounds are particularly useful to image target sites such as tumour sites and sites of infection.

Abstract: This invention relates to radiolabeled peptide compositions for radiopharmaceutical use and, more specifically, to radiolabeled peptides for diagnostic or therapeutic use having an unmodified carboxy terminal amino acid. The radiopharmaceutical composition may be used for targeting a selected biological site. The radiolabeled peptide is characterized by having its carboxy terminal amino acid in its carboxylic acid form and the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent. The radiopharmaceutical composition preferably comprises a radiolabeled peptide selected from the group consisting of somatostatin, an analog of somatostatin, a derivative of somatostatin and peptides capable of binding to the somatostatin receptor, where the peptide is coupled to a diagnostic or therapeutic radionuclide by a chelating agent has its carboxy terminal amino acid in its carboxylic acid form.